The stocks highlighted below are only a starting sample from this theme, while the full screen surfaced around 100 more companies with similarly strong growth stories and meaningful insider ownership that are not covered here. If you want to identify potential standouts for your own watchlist, head straight to the Fast Growing Stocks With High Insider Ownership screener to filter and analyze the set for your highest conviction ideas.
Predictive Discovery (ASX:PDI)
Overview: Predictive Discovery is a West Africa focused gold company that currently operates the Kiniero and Nampala mines and is advancing the large scale Bankan Gold project in north east Guinea. The business aims to grow into a multi asset producer by using cash flow from existing operations to fund development and exploration across its 9.5 million ounce resource base.
Market Cap: A$4.0 billion
Predictive Discovery may appeal to investors seeking exposure to expanding gold production supported by management with meaningful alignment. The merger with Robex has created a larger platform with two producing mines and the Bankan project under development, while recent quarterly updates report strong throughput and recoveries at Kiniero and solid group production. Some analysts outline a path to scale, with expectations of revenue growth and improving profitability, and some models suggest the stock screens as significantly undervalued on certain cash flow metrics and price targets. At the same time, investors need to be comfortable with permitting risk in Guinea, a relatively short cash runway and reliance on external funding, which could be important if project execution or gold markets differ from current plans.
Predictive Discovery’s push to become a multi asset gold producer has some investors focusing on growth, while others worry about Guinea permitting and funding. Get the full picture in the 2 key rewards and 3 important warning signs (2 are major!)
Build your own high conviction growth and alignment shortlist
Predictive Discovery and the other two stocks in this article all came from the same screener, which is only a starting point. Use our flexible Screener to mix filters like insider ownership, valuation, growth and risks so the results fit your style, or jump straight into our curated Investing Ideas for ready made themes.
Telix Pharmaceuticals (ASX:TLX)
Overview: Telix Pharmaceuticals develops and sells radiopharmaceutical products that help doctors pinpoint and treat cancers, combining precision imaging agents with targeted therapies for conditions such as prostate, kidney and brain cancers across key global markets.
Operations: Telix generates most of its roughly US$804 million in revenue from Precision Medicine at about US$622 million, with additional contributions from Manufacturing Solutions at about US$245 million and Therapeutics at about US$9 million.
Market Cap: A$5.9 billion
Telix Pharmaceuticals sits at the crossroads of strong revenue growth and an ambitious cancer therapy pipeline, which helps explain why many investors keep it on their radar despite current losses. The core imaging agents Illuccix and Gozellix already support hundreds of millions in annual sales. Late stage trials such as ProstACT Global and LUTEON are testing whether Telix can turn that imaging footprint into higher margin therapeutics. At the same time, a higher risk funding mix, rising R&D and an SEC subpoena on pipeline disclosures mean the story is not without real pressure points. With analysts seeing potential upside to the current share price and management guiding to almost US$1b of revenue in 2026, upcoming trial and regulatory milestones could be pivotal for this stock.
Telix Pharmaceuticals is turning radiopharmaceutical buzz into real revenue momentum, yet the story is still incomplete. See how the analyst forecasts for Telix Pharmaceuticals stack up against rising trial costs and that SEC subpoena twist.
Lindian Resources (ASX:LIN)
Overview: Lindian Resources is a Perth based minerals explorer focused on the Kangankunde Rare Earths project in Malawi, with additional exploration interests in gold, bauxite and rare earth element deposits across Tanzania, Guinea, Malawi, Australia and Singapore.
Market Cap: A$1.5 billion
Lindian Resources is on the radar for investors watching the rare earth supply chain as it moves from explorer to planned producer at Kangankunde. Management is targeting first production from the Malawi project and initial processing from the newly acquired SARECO facility in Kazakhstan around Q4 2026. If this is achieved, it could turn today’s very low revenue base into something more substantial. Forecasts indicate rapid potential increases in revenue and earnings. The company is still loss making, highly reliant on external borrowing and has a young, non independent board and management team. The recent confirmation of Kangankunde’s licence status and a new sales hub in Singapore add to the story. However, the balance between growth potential and elevated funding and governance risk is a key consideration for investors.
Lindian Resources is racing to turn Kangankunde into a rare earths producer, yet funding pressure and a young board leave key questions unanswered. Get the full 1 key reward and 3 important warning signs (2 are major!)
Seeking Alternatives Before The Crowd Moves
Fresh stock stories can move from quiet to flying in weeks. Use this moment before the crowd catches on, while the data still matters, and consider acting during this period.
- Look for potential breakout strength in companies that pair cash generation with sturdy balance sheets through the curated list of solid balance sheet and fundamentals (20 results) while valuations may still be compelling.
- Track momentum in established producers with exposure to metal prices using the focused 30 elite gold producer stocks while many investors may not yet be paying close attention.
- Monitor early developments in power and grid upgrades by scanning the specialist 36 power grid technology and infrastructure stocks ahead of broader interest that could follow infrastructure spending headlines.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com